The annual meeting of the American College of Gastroenterology was held from Oct. 24 to 29 in Phoenix, attracting participants from around the world, including gastroenterology and digestive disease ...

Novo Nordisk (NVO) and Eli Lilly (LLY) are nearing a deal with the White House on obesity drug pricing, with initial reports suggesting that the companies will price obesity drugs at $149 per month ...

Semaglutide or tirzepatide should be first-line drugs for obesity and most of its related complications, new guidance from the European Association for the Study of Obesity recommended. The authors of ...

The three GLP-1 receptor agonist (RA) drugs liraglutide (Victoza), semaglutide (Ozempic), and dulaglutide (Trulicity) provided similar cardiovascular and kidney benefits in people with type 2 diabetes ...

A qualitative study of semaglutide (Ozempic, Wegovy) purchases over the internet without a prescription uncovered scams, low purity levels, and possible contamination of products. Quality testing of ...

Danish pharmaceutical giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced Thursday an unsolicited ...

In the trial, 136 adults with overweight or obesity were randomly assigned to receive weekly injections of nimacimab, semaglutide, both drugs together, or placebo. Participants who received nimacimab ...

Microdosing GLP-1 weight loss drugs like semaglutide is trendy, with supporters touting benefits such as lower costs and potentially fewer side effects. But some doctors are skeptical, calling it ...

Dr. Troy Mensen is a family medicine doctor based in the Chicago area. He completed his undergraduate degree at the University of Northern Iowa and his doctorate at Des Moines University College of ...

The discovery of GLP-1 and its role in regulating blood glucose was a major scientific breakthrough in diabetes research, yet turning this peptide hormone into an effective medication was no easy task ...

Feasibility of implementing a virtual nursing-led smoking cessation clinic for patients with cancer. Absolute change in metabolic markers at 24 months between study groups.

As of Oct. 17, the FDA has approved more than a dozen glucagon-like peptide-1 receptor agonists for diabetes, weight loss, cardiovascular disease and other indications.